Literature DB >> 22964580

Multiple roles of p53-related pathways in somatic cell reprogramming and stem cell differentiation.

Lan Yi1, Chiwei Lu, Wenwei Hu, Yvonne Sun, Arnold J Levine.   

Abstract

The inactivation of p53 functions enhances the efficiency and decreases the latency of producing induced pluripotent stem cells (iPSC) in culture. The formation of iPSCs in culture starts with a rapid set of cell divisions followed by an epigenetic reprogramming of the DNA and chromatin. The mechanisms by which the p53 protein inhibits the formation of iPSCs are largely unknown. Using a temperature sensitive mutant of the p53 (Trp53) gene, we examined the impact of the temporal expression of wild type p53 in preventing stem cell induction from somatic cells. We also explored how different p53 mutant alleles affect the reprogramming process. We found that little or no p53 activity favors the entire process of somatic cell reprogramming. Reactivation of p53 at any time point during the reprogramming process not only interrupted the formation of iPSCs, but also induced newly formed stem cells to differentiate. Among p53-regulated genes, p21 (Cdkn1a), but not Puma (Bbc3) played a partial role in iPSCs formation probably by slowing cell division. Activation of p53 functions in iPSCs induced senescence and differentiation in stem cell populations. High rate of birth defects and increases in DNA methylation at the IGF2-H19 loci in female offspring of p53 knockout mice suggested that the absence of p53 may give rise to epigenetic instability in a stochastic fashion. Consistently, selected p53 missense mutations showed differential effects on the stem cell reprogramming efficiency in a c-Myc dependent manner. The absence of p53 activity and functions also contributed to an enhanced efficiency of iPSC production from cancer cells. The production of iPSCs in culture from normal and cancer cells, although different from each other in several ways, both responded to the inhibition of reprogramming by the p53 protein. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22964580     DOI: 10.1158/0008-5472.CAN-12-1451

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.

Authors:  Evangelia Loizou; Ana Banito; Geulah Livshits; Yu-Jui Ho; Richard P Koche; Francisco J Sánchez-Rivera; Allison Mayle; Chi-Chao Chen; Savvas Kinalis; Frederik O Bagger; Edward R Kastenhuber; Benjamin H Durham; Scott W Lowe
Journal:  Cancer Discov       Date:  2019-05-08       Impact factor: 39.397

Review 2.  The Role of the p53 Protein in Stem-Cell Biology and Epigenetic Regulation.

Authors:  Arnold J Levine; Anna M Puzio-Kuter; Chang S Chan; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

Review 3.  Assessing the risks of genotoxicity in the therapeutic development of induced pluripotent stem cells.

Authors:  So Gun Hong; Cynthia E Dunbar; Thomas Winkler
Journal:  Mol Ther       Date:  2012-12-04       Impact factor: 11.454

4.  Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.

Authors:  Marianna L Ianzano; Stefania Croci; Giordano Nicoletti; Arianna Palladini; Lorena Landuzzi; Valentina Grosso; Dario Ranieri; Massimiliano Dall'Ora; Ilaria Santeramo; Milena Urbini; Carla De Giovanni; Pier-Luigi Lollini; Patrizia Nanni
Journal:  Oncotarget       Date:  2014-01-15

Review 5.  Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Authors:  Ruoji Zhou; An Xu; Julian Gingold; Louise C Strong; Ruiying Zhao; Dung-Fang Lee
Journal:  Trends Pharmacol Sci       Date:  2017-08-14       Impact factor: 14.819

6.  Lineage Plasticity in Cancer Progression and Treatment.

Authors:  Clémentine Le Magnen; Michael M Shen; Cory Abate-Shen
Journal:  Annu Rev Cancer Biol       Date:  2017-12-01

Review 7.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

8.  Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells.

Authors:  Antoine Tanne; Luciana R Muniz; Anna Puzio-Kuter; Katerina I Leonova; Andrei V Gudkov; David T Ting; Rémi Monasson; Simona Cocco; Arnold J Levine; Nina Bhardwaj; Benjamin D Greenbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

9.  Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types.

Authors:  Ágnes Holczbauer; Valentina M Factor; Jesper B Andersen; Jens U Marquardt; David E Kleiner; Chiara Raggi; Mitsuteru Kitade; Daekwan Seo; Hirofumi Akita; Marian E Durkin; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2013-03-19       Impact factor: 22.682

Review 10.  Cancer: pathological nuclear reprogramming?

Authors:  Colin R Goding; Duanqing Pei; Xin Lu
Journal:  Nat Rev Cancer       Date:  2014-07-17       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.